We conducted a meta-analysis of six large randomized controlled trials (RCTs), enrolling more than 47,000 patients with T2DM and varying risks of cardiovascular disease (CVD) and chronic kidney disease (CKD), to evaluate the effect of SGLT2 inhibitors on hospitalization for heart failure (HHF). Here, SLC5A2 is linked to chronic kidney disease.